LCOF Grants Program
The Lung Cancer Online Grants Program is based on the premise that
additional sources of funding are needed to accelerate advances
in lung cancer research and to spur progress in improving the quality
of care, and the duration and quality of life of people with lung
The Grants Program supports the work of qualified individuals and
groups conducting research in lung cancer and related fields and
funds fellowships to train lung cancer specialists.
LCOF funding priorities are set by the Board of Directors in consultation
with members of the Scientific Advisory Board. All funding decisions are solely the
responsibility of the LCOF Board of Directors. LCOF does not accept unsolicited grant proposals.
Grants & Awards - 2005
WALC-LCOF Career Development Award
This 2-year $100,000 award is for junior clinical and basic investigators
involved in lung cancer etiology, prevention, and treatment. Women
Against Lung Cancer (WALC) and The Lung Cancer Online Foundation
(LCOF) are co-sponsoring this program to create a critical mass
of lung cancer researchers to ensure effective translation of basic
and behavioral research discoveries into patient therapies to reduce
lung cancer incidence, morbidity and mortality.
Hayley McDaid, PhD, of the Albert Einstein College of
Medicine, was selected as the inaugural recipient of the WALC-LCOF
Career Development Award for her research into how lung cancer cells
respond to targeted therapies and how the cells become resistant
to the effects of these drugs. Dr. McDaid's work will address the
urgent need to identify and test novel therapeutic strategies that
take into account the molecular complexity and heterogeneity of
Grants & Awards - 2003 & 2004
The Role of Estrogen in Lung Cancer
Principal Investigator: Ann G. Schwartz, PhD,
MPH, Karmanos Cancer Institute
Abstract: In 2003, an estimated 80,100 women in the US
were diagnosed with lung cancer and 68.800 died from this disease.
While lung cancer incidence rates among men have leveled off, rates
among women continue to increase. While tobacco smoke is the major
risk factor for this disease, studies have shown variation in susceptibility
to tobacco smoke by sex. In addition, the proportion of nonsmoking
lung cancer cases in women is about double that in men suggesting
that even nonsmoking women may be more susceptible to lung carcinogens
than nonsmoking men. A role for hormones in determining lung cancer
risk is suggested by the reported gender differences in susceptibility.
The aim of this study is to evaluate the contribution of tobacco
exposure (both active and passive), estrogen use, and reproductive
history in determining risk of lung cancer in women using data from
the Women's Health Initiative (WHI) Observational Study. WHI enrolled
93,676 women and continues to follow these women for health outcomes.
Reproductive history, use of estrogen replacement therapy and oral
contraceptives, and tobacco exposure were collected. In this cohort
of women, 460 new lung cancer developed during follow-up. The data
from this study provide an excellent, well-developed resource for
the evaluation of risk factors for lung cancer in women, focusing
on estrogen exposures.
Research in Bronchioloalveolar Carcinoma (BAC) of the Lung
Principal Investigator: David C. Christiani,
MD, MPH, MS, Harvard School of Public Health
Abstract: Recent research studies have observed an increase
of the BAC cell type within adenocarcinoma, currently the most widespread
lung cancer subtype. BAC has unique features, such as involvement
of both lungs, comparatively slow course, and increasing incidence
over the past 20 years. Although changes in cigarette types and
in smoking patterns may explain some of the shifts in the major
subtypes, they do not appear to account for the apparent increase
in BAC—a type that appears in non-smokers as well. Although
lung cancer is heavily studied, we know very little about BAC. This
research study will help us to understand the epidemiology of BAC,
how we might develop ways of preventing it, and also about its molecular
characteristics in order to help develop more effective treatments.
A Randomized Controlled Trial of Methylphenidate for Fatigue
in Patients with Advanced NSCLC
Principal Investigator: Jennifer Temel, MD,
Massachusetts General Hospital
Abstract: Non-small cell lung cancer (NSCLC) is a prevalent
disease and the majority of patients are diagnosed with advanced
stage disease at presentation. These patients experience a high
symptom burden and fatigue is one of the most common and distressing
symptoms they experience. Cancer-related fatigue can be very difficult
to manage when there is no clear underlying etiology, such as anemia.
Psychostimulants, such as methylphenidate, have been examined in
cancer patients for the treatment of depression, cognitive dysfunction
and fatigue. However, there are no published randomized, controlled
studies clearly demonstrating their efficacy cancer-related fatigue.
This study will examine the role of methylphenidate for the treatment
of cancer-related fatigue in patients with advanced lung cancer.
Participants will be randomized to methylphenidate or placebo and
will be monitored for fatigue, quality of life, depression, and
drug side effects.